FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Lymphokine > Interleukin

Interleukin

Interleukin patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

10/23/14 - 20140314709 - Il-2 derivatives polypeptides with agonist activity for therapy of cancer and chronic infections
The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in...

10/23/14 - 20140314710 - Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p402), and the IL-23. To facilitate the studies on p402 and p40, neutralizing monoclonal antibodies (mAb)...

10/23/14 - 20140314711 - Il-22 polypeptides and il-22 fc fusion proteins and methods of use
The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof....

10/23/14 - 20140314712 - Fusion protein comprising an interleukin 4 and interleukin
The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing...

10/16/14 - 20140308237 - Use of inclusion bodies as therapeutic agents
The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by...

10/16/14 - 20140308238 - Immunomodulating compositions and methods of use thereof
The invention is directed to β1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The β1-6 glucans of certain embodiments of the invention...

10/16/14 - 20140308239 - Chimeric cytokine formulations for ocular delivery
Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery....

10/16/14 - 20140308240 - Therapeutic agent for infections, and treatment method using same
(Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of...

10/16/14 - 20140308241 - Biomarkers for t cell malignancies and uses thereof
Described are biomarkers including TOX useful for the diagnosis or prognosis of T cell malignancy. A level of a biomarker is determined in a sample from a subject and compared to a control level, wherein an increased level of the biomarker in the sample relative to the control level indicates...

10/09/14 - 20140301974 - Extended recombinant polypeptides and compositions comprising same
The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and...

10/09/14 - 20140301975 - Methods for treating blood disorders
Methods of treating blood disorders are described....

10/09/14 - 20140301976 - Novel hydroxamates as therapeutic agents
The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also...

10/09/14 - 20140301977 - Overload and elute chromatography
The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant by overloading a chromatography material and eluting the product....

10/02/14 - 20140294758 - Light chain immunoglobulin fusion proteins and methods of use thereof
Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active....

10/02/14 - 20140294759 - Targeting regulatory t cells with heterodimeric proteins
The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells....

10/02/14 - 20140294760 - Novel cell and therapeutical and diagnostical methods based thereon
The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening...

10/02/14 - 20140294761 - Treatments for migraine and related disorders
Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies...

10/02/14 - 20140294762 - Glycopegylation methods and proteins/peptides produced by the methods
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide....

10/02/14 - 20140294763 - Peptidomimetic protease inhibitors
The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds...

10/02/14 - 20140294764 - Compounds and compositions used to epigenetically transform cells and methods related thereto
This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells,...

10/02/14 - 20140294765 - Lsr antibodies, and uses thereof for treatment of cancer
This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer....

09/25/14 - 20140286896 - Molecular diagnostic panel of eosinophilic gastrointestinal disorders
Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the...

09/25/14 - 20140286897 - Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin)....

09/25/14 - 20140286898 - Interleukin-2 muteins for the expansion of t-regulatory cells
Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also,...

09/18/14 - 20140271539 - Novel use of members of il-10 cytokine family
The invention relates to a novel use of the members of the IL-10 cytokine family in wound healing. Particularly, the invention relates to the use of the member of the IL-10 cytokine family in the promotion of the proliferation and the migration of keratinocyte cells in wound healing....

09/18/14 - 20140271540 - 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one, salts thereof and methods of using the same in combination therapy
or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially....

09/11/14 - 20140255339 - Compounds and pharmaceutical compositions for the treatment of viral infections
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents....

09/11/14 - 20140255340 - Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor....

09/11/14 - 20140255341 - Tumor selective chemokine modulation
Therapies effective for the treatment and prevention of cancer and other diseases are disclosed. These methods include the administration of therapeutically effective amounts of agents that increase the local production of effector cell-attracting chemokines within tumor lesions, with concomitant suppression of local production of undesirable chemokines that attract regulatory T(reg)...

09/11/14 - 20140255342 - Thiophene derivatives
R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application....

09/11/14 - 20140255343 - Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine
The object of the invention is a DNA vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin H5 of an influenza virus and application of the DNA vaccine. According to the invention, one or two-fold immunisation of hens with DNA vaccine containing a cDNA encoding the modified...

09/04/14 - 20140248235 - Methods of use for il-22 promoting rejuvenation of thymic and bone marrow function
The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer...

09/04/14 - 20140248236 - Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes....

08/28/14 - 20140242025 - Multimeric il-15 soluble fusion molecules and methods of making and using same
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus)....

08/28/14 - 20140242026 - Compounds, compositions, and methods for preventing metastasis of cancer cells
Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells....

08/21/14 - 20140234251 - Purine nucleoside analogues for treating flaviviridae including hepatitis c
This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a...

08/21/14 - 20140234252 - Composition and methods for the treatment of degenerative retinal conditions
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation....

08/14/14 - 20140227221 - Methods of treating multiple myeloma and resistant cancers
Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents....

08/14/14 - 20140227222 - Cyclin dependent kinase inhibitors and methods of use
The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or...

08/14/14 - 20140227223 - Pegylated interleukin-10
Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus...

08/07/14 - 20140219955 - Fusion molecules and il-15 variants
The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention....

08/07/14 - 20140219956 - Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell,...

07/31/14 - 20140212378 - Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
The described invention comprises a method for detecting the onset or monitoring the recurrence of chronic graft versus host disease (cGVHD) in a transplantation patient. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from the transplantation patient and analyzing the isolated PBMCs to detect a biomarker specific for a...

07/31/14 - 20140212379 - Il-1 binding proteins
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions....

07/31/14 - 20140212380 - Targets and agents for the treatment of impaired bone fracture healing
The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, and an agonist of IL-8 receptor, for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but...

07/24/14 - 20140205560 - Multimeric il-15 soluble fusion molecules and methods of making and using same
The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble...

07/24/14 - 20140205561 - Mitigation of cutaneous injury with il-12
The present application relates to treatment of cutaneous wounds using IL-12. The methods of the invention result in improved wound closure. The methods comprise treating cutaneous wounds using topical, subcutaneous, and/or intramuscular administration of IL-12....

07/24/14 - 20140205562 - Il-1 binding proteins
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions....

07/24/14 - 20140205563 - Compositions derived from stem cell released molecules & methods for formulation thereof
Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's...

07/24/14 - 20140205564 - Hepatitis c virus inhibitors
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection....

07/24/14 - 20140205565 - Compositions and methods for treating organ dysfunction
A method of retarding cellular senescence comprising (i) providing an extracellular matrix (ECM) composition comprising ECM from an adolescent tissue source, the ECM comprising an exogenously added cytokine, and (ii) administering ECM composition to an organ with cells exhibiting cellular senescence, wherein, the cytokine interacts with at least one molecule...